Skip to content
DataLookout
Menu

PNOC020 rMBNCT07492316

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reopened
    • Study sites: 1 to 2
  2. Notable Eligibility criteria expanded, about 36 words
    • Enrollment closed, study ongoing
    • Site details revised
  3. Minor Start date changed from estimate of May 15, 2026 to Apr 24, 2026v3
  4. Notable Recruitment opened
    • Study sites: 0 to 1
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Manufacturing feasibility
Timeframe: from the date of surgery until administration of third vaccine, up to 15 weeks
Safety of RNA-LP vaccine
Timeframe: First vaccine through 14 days after administration of the 3rd vaccine
Determination of Maximum Tolerated Dose
Timeframe: up to 60 months

Arms and interventions

recurrent/progressive Medulloblastoma (rMB)Experimental

Biologicals: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)

Sites

2 sites in 1 country